Amryt Pharma plc Revenue 2011-2026 | AMYT

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Amryt Pharma plc

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
223 M	183 M	58.1 M	17.1 M	15.3 M	1.42 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
223 M	1.42 M	82.9 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
ADMA Biologics ADMA	510 M	$ 15.87	-4.08 %	$ 3.78 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AbCellera Biologics ABCL	75.1 M	$ 3.54	-2.62 %	$ 1.06 B	Canada
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	912 K	$ 0.82	-0.73 %	$ 4.47 M	China
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Apellis Pharmaceuticals APLS	1 B	$ 20.36	2.49 %	$ 2.57 B	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	614 M	$ 75.13	-1.83 %	$ 1.45 B	USA
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	242 K	$ 1.51	-7.36 %	$ 385 M	Britain
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	42.3 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	638 M	$ 162.19	-1.15 %	$ 8.07 B	USA
BridgeBio Pharma BBIO	502 M	$ 64.72	-2.73 %	$ 12.4 B	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	78.6 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
BioLineRx Ltd. BLRX	28.9 M	$ 2.86	1.78 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	3.22 B	$ 60.15	-0.46 %	$ 11.5 B	USA
Equillium EQ	36.1 M	$ 1.7	-3.14 %	$ 59 M	USA
Burford Capital Limited BUR	330 M	$ 8.29	-1.02 %	$ 1.35 B	Britain
Cabaletta Bio CABA	0.006	$ 3.3	-3.89 %	$ 3.85 M	USA
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	156 M	$ 3.02	-5.63 %	$ 1.08 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Capricor Therapeutics CAPR	25.2 M	$ 25.16	-1.33 %	$ 674 M	USA
Agios Pharmaceuticals AGIO	54 M	$ 27.77	-1.49 %	$ 1.61 B	USA